Amphastar Pharmaceuticals Inc. (AMPH)
Amphastar Pharmaceuticals: Shares Are Interesting, And Options Even More
Amphastar is undervalued (~71% upside), but lacks an economic moat and faces modest growth, so I favor a cautious gradual strategy. The business is defensive, with a diversified product mix and pipeline, but faces headwinds from competition, tariffs, and patent expirations. My base-case DCF-based fair value is $38.23; even in a pessimistic scenario, the stock seems at least fairly valued, limiting downside risk.
What Makes Amphastar (AMPH) a New Buy Stock
Amphastar (AMPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Amphastar (AMPH) is Poised for a Turnaround After Losing 13.1% in 4 Weeks
Amphastar (AMPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Amphastar Pharmaceuticals: Navigating Through An Inflection Year
Amphastar Pharmaceuticals posted Q1 results last week that beat the bottom-line consensus. The stock appears cheap at under eight times forward earnings, but the company is going through an 'inflection year' with flat revenue growth and declining profits. Growth should return in 2026 thanks to upcoming product launches. Is the stock cheap enough to buy the recent dip in the shares?
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amphastar Pharmaceuticals Inc. (AMPH) Q1 2025 Earnings Call Transcript
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants David Amsellem - Piper Sandler Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Ekaterina Knyazkova - JPMorgan Operator Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants are in a listen-only mode.
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.04 per share a year ago.
Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock?
Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
On Thursday, Amphastar Pharmaceuticals Inc. AMPH reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents.
Amphastar: Earnings Miss, Margins Drop
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.
Amphastar Pharmaceuticals Inc. (AMPH) Q4 2024 Earnings Call Transcript
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants Jason Gerberry - Bank of America Cerena Chen - Wells Fargo Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Serge Belanger - Needham & Company Operator Greetings and welcome to the Amphastar Pharmaceuticals Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode.
